false 0000310158 0000310158 2020-06-24 2020-06-24 0000310158 us-gaap:CommonStockMember 2020-06-24 2020-06-24 0000310158 mrk:Sec1.125NotesDue2021Member 2020-06-24 2020-06-24 0000310158 mrk:Sec0.500NotesDue2024Member 2020-06-24 2020-06-24 0000310158 mrk:Sec1.875NotesDue2026Member 2020-06-24 2020-06-24 0000310158 mrk:Sec2.500NotesDue2034Member 2020-06-24 2020-06-24 0000310158 mrk:Sec1.375NotesDue2036Member 2020-06-24 2020-06-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 24, 2020

 

Merck & Co., Inc.

(Exact name of registrant as specified in its charter)

 

New Jersey

 

1-6571

 

22-1918501

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

2000 Galloping Hill Road, Kenilworth, NJ

 

07033

(Address of principal executive offices)

 

(Zip code)

(Registrant’s telephone number, including area code): (908) 740-4000

Not Applicable

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

 

Trading

Symbol(s)

 

Name of Each Exchange

on which Registered

Common Stock ($0.50 par value)

 

MRK

 

New York Stock Exchange

1.125% Notes due 2021

 

MRK/21

 

New York Stock Exchange

0.500% Notes due 2024

 

MRK24

 

New York Stock Exchange

1.875% Notes due 2026

 

MRK/26

 

New York Stock Exchange

2.500% Notes due 2034

 

MRK/34

 

New York Stock Exchange

1.375% Notes due 2036

 

MRK36A

 

New York Stock Exchange

 

 


Item 8.01 Other Events.

On June 24, 2020, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $1,000,000,000 aggregate principal amount of 0.750% Notes due 2026 (the “2026 Notes”), $1,250,000,000 aggregate principal amount of 1.450% Notes due 2030 (the “2030 Notes”), $1,000,000,000 aggregate principal amount of 2.350% Notes due 2040 (the “2040 Notes”) and $1,250,000,000 aggregate principal amount of 2.450% Notes due 2050 (the “2050 Notes” and, together with the 2026 Notes, the 2030 Notes and the 2040 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-224017).

The Notes are being issued under an indenture dated as of January 6, 2010, between the Company and U.S. Bank Trust National Association, as trustee, a copy of which was attached as Exhibit 4.1 to the Company’s Current Report on Form 8-K previously filed with the Securities and Exchange Commission on December 10, 2010 and is incorporated herein by reference. Copies of the officers’ certificate for each series of the Notes (including forms of each of the respective Notes attached thereto) pursuant to Section 301 of the indenture governing the Notes are attached hereto as exhibits 4.1, 4.2, 4.3 and 4.4 and are incorporated herein by reference. The legal opinion related to these Notes is attached hereto as Exhibit 5.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit 4.1

   

0.750% Notes due 2026 Officers’ Certificate of the Company dated June 24, 2020, including form of the 2026 Notes.

         
 

Exhibit 4.2

   

1.450% Notes due 2030 Officers’ Certificate of the Company dated June 24, 2020, including form of the 2030 Notes.

         
 

Exhibit 4.3

   

2.350% Notes due 2040 Officers’ Certificate of the Company dated June 24, 2020, including form of the 2040 Notes.

         
 

Exhibit 4.4

   

2.450% Notes due 2050 Officers’ Certificate of the Company dated June 24, 2020, including form of the 2050 Notes.

         
 

Exhibit 5.1

   

Opinion and Consent of Jennifer Zachary, Esq., Executive Vice President, General Counsel and Corporate Secretary of the Company.

         
 

Exhibit 23.1

   

Consent of Jennifer Zachary, Esq., Executive Vice President, General Counsel and Corporate Secretary of the Company (contained in Exhibit 5.1 to this Current Report on Form 8-K).

         
 

Exhibit 104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Merck & Co., Inc.

             

Date: June 24, 2020

 

 

By:

 

/s/ Faye C. Brown

 

 

 

Faye C. Brown

 

 

 

Senior Assistant Secretary

Merck (NYSE:MRK)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Merck Charts.